tetano
Editor, Senior Moderator
Int J Biol Macromol
. 2024 Jun 26:133453.
doi: 10.1016/j.ijbiomac.2024.133453. Online ahead of print. The recombinant vaccine of Lactobacillus plantarum elicits immune protection against H1N1 and H9N2 influenza virus infection
Yuanbao Zhou[SUP] 1 [/SUP], Zhipeng Lin[SUP] 1 [/SUP], Jiaqing Fang[SUP] 1 [/SUP], Zhihao Wang[SUP] 1 [/SUP], Jinli Guo[SUP] 1 [/SUP], Guohong Li[SUP] 2 [/SUP], Qiaoxia Xu[SUP] 2 [/SUP], Meilin Jin[SUP] 3 [/SUP], Huanchun Chen[SUP] 4 [/SUP], Jiahui Zou[SUP] 5 [/SUP], Hongbo Zhou[SUP] 6 [/SUP]
Affiliations
Influenza A virus (IAV) causes annual epidemics and occasional pandemics, resulting in significant economic losses and numerous fatalities. Current vaccines, typically administered through injection, provide limited protection due to the frequent antigenic shift and drift of IAV strains. Therefore, the development of alternative broad-spectrum vaccine strategies is imperative. Lactic acid bacteria (LAB) represent promising candidates for vaccine engineering due to their low cost, high safety profile, and suitability for oral administration. In this study, we identified a strain of Lactobacillus plantarum (Lp) that is resistant to acid and bile salts and capable of colonizing the intestines of mice. Subsequently, we employed the RecE/T gene editing system to integrate headless hemagglutinins (mini-HA) into the genome of Lp, generating Lp-mini-HA-SP. Remarkably, immunization with Lp-mini-HA-SP elicited serum IgG antibody responses and conferred immune protection against H9N2 and H1N1 influenza virus challenges. Collectively, our findings offer a novel approach for the development of orally administered IAV vaccines and hold significant potential for future drug development endeavors.
Keywords: Influenza virus; Lactobacillus plantarum; mini-HA.
. 2024 Jun 26:133453.
doi: 10.1016/j.ijbiomac.2024.133453. Online ahead of print. The recombinant vaccine of Lactobacillus plantarum elicits immune protection against H1N1 and H9N2 influenza virus infection
Yuanbao Zhou[SUP] 1 [/SUP], Zhipeng Lin[SUP] 1 [/SUP], Jiaqing Fang[SUP] 1 [/SUP], Zhihao Wang[SUP] 1 [/SUP], Jinli Guo[SUP] 1 [/SUP], Guohong Li[SUP] 2 [/SUP], Qiaoxia Xu[SUP] 2 [/SUP], Meilin Jin[SUP] 3 [/SUP], Huanchun Chen[SUP] 4 [/SUP], Jiahui Zou[SUP] 5 [/SUP], Hongbo Zhou[SUP] 6 [/SUP]
Affiliations
- PMID: 38942402
- DOI: 10.1016/j.ijbiomac.2024.133453
Influenza A virus (IAV) causes annual epidemics and occasional pandemics, resulting in significant economic losses and numerous fatalities. Current vaccines, typically administered through injection, provide limited protection due to the frequent antigenic shift and drift of IAV strains. Therefore, the development of alternative broad-spectrum vaccine strategies is imperative. Lactic acid bacteria (LAB) represent promising candidates for vaccine engineering due to their low cost, high safety profile, and suitability for oral administration. In this study, we identified a strain of Lactobacillus plantarum (Lp) that is resistant to acid and bile salts and capable of colonizing the intestines of mice. Subsequently, we employed the RecE/T gene editing system to integrate headless hemagglutinins (mini-HA) into the genome of Lp, generating Lp-mini-HA-SP. Remarkably, immunization with Lp-mini-HA-SP elicited serum IgG antibody responses and conferred immune protection against H9N2 and H1N1 influenza virus challenges. Collectively, our findings offer a novel approach for the development of orally administered IAV vaccines and hold significant potential for future drug development endeavors.
Keywords: Influenza virus; Lactobacillus plantarum; mini-HA.